Valuation: Novacyt

Market Cap 33.79M 37.58M 31.53M 28.58M 53.65M 3.58B 53.98M 378M 148M 1.86B 141M 138M 5.97B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 35.74M 39.75M 33.35M 30.23M 56.76M 3.78B 57.11M 400M 156M 1.96B 149M 146M 6.31B EV / Sales 2026 *
1.17x
EV / Sales 2027 * 1.11x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
3 months+18.85%
6 months+18.85%
Current year+11.84%
Current year 0.48
Extreme 0.48
0.57
1 year 0.48
Extreme 0.48
0.57
3 years 0.48
Extreme 0.48
1.25
5 years 0.48
Extreme 0.48
5.77
10 years 0
Extreme 0
16
Manager TitleAgeSince
Chief Executive Officer 53 2024-04-30
Director of Finance/CFO 44 2019-12-31
Chief Operating Officer - 2021-10-31
Director TitleAgeSince
Director/Board Member 75 2006-07-02
Director/Board Member 60 2017-06-26
Director/Board Member 44 2024-01-01
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 37.82M
-2.01%-7.86%+54.60%+70.97% 70.44B
+3.84%-11.02%+8.59%+58.77% 50.31B
+3.35%+1.42%+11.85%+37.39% 47.51B
+0.51%+1.72%+28.23%+31.95% 42.91B
+3.34%-2.97%+310.32%+471.22% 40.39B
+1.13%-3.18%+9.81%+102.62% 39.69B
+0.06%-1.43%+10.47%+43.27% 30.59B
-2.95%-14.09%+37.94%+1.30% 26.8B
+0.33%-6.68%-13.37%-8.33% 22.36B
Average +0.76%-5.58%+50.94%+89.90% 41.22B
Weighted average by Cap. +0.91%-5.44%+53.94%+95.36%

Financials

2026 *2027 *
Net sales 30.52M 33.95M 28.49M 25.82M 48.47M 3.23B 48.77M 342M 133M 1.68B 127M 125M 5.39B 34.86M 38.77M 32.53M 29.49M 55.36M 3.69B 55.7M 390M 152M 1.92B 146M 142M 6.16B
Net income - -
Net Debt 1.96M 2.18M 1.83M 1.65M 3.11M 207M 3.13M 21.91M 8.55M 107M 8.17M 7.99M 346M 4.84M 5.39M 4.52M 4.1M 7.69M 512M 7.74M 54.23M 21.17M 266M 20.22M 19.78M 855M
Projected Income Statement - Annual - Novacyt
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
228

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Novacyt